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Abstract
Background—Cannabis use rates are increasing among adults in the United States (US) while
the perception of harm is declining. This may result in an increased prevalence of cannabis use
disorder and the need for more clinical trials to evaluate efficacious treatment strategies. Clinical
trials are the gold standard for evaluating treatment, yet study samples are rarely representative of
the target population. This finding has not yet been established for cannabis treatment trials. This
study compared demographic and cannabis use characteristics of a cannabis cessation clinical trial
sample (run through National Drug Abuse Treatment Clinical Trials Network) with three
nationally representative datasets from the US; 1) National Survey on Drug Use and Health, 2)
National Epidemiologic Survey on Alcohol and Related Conditions-III, and 3) Treatment Episodes
Data Set – Admissions.

Author Manuscript

Methods—Comparisons were made between the clinical trial sample and appropriate cannabis
using sub-samples from the national datasets, and propensity scores were calculated to determine
the degree of similarity between samples.
Results—Results showed that the clinical trial sample was significantly different from all three
national datasets, with the clinical trial sample having greater representation among older adults,
African Americans, Hispanic/Latinos, adults with more education, non-tobacco users, and daily
and almost daily cannabis users.
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Conclusions—These results are consistent with previous studies of other substance use disorder
populations and extend sample representation issues to a cannabis use disorder population. This
illustrates the need to ensure representative samples within cannabis treatment clinical trials to
improve the generalizability of promising findings.
Keywords
Cannabis; marijuana; cannabis use disorder; treatment; clinical trial; sample representativeness;
generalizability

1. Introduction

Author Manuscript
Author Manuscript

Cannabis is the most commonly used illicit substance in the United States (US) (Center for
Behavioral Health Statistics and Quality, 2015). Cannabis use rates are increasing among
adults (Grucza et al., 2016; Hasin et al., 2016), while the perception of harm associated with
cannabis is declining (Berg et al., 2015; Johnston et al., 2015; Pacek et al., 2015; Sinclair et
al., 2013). Legislation surrounding cannabis use and possession is rapidly changing in the
US, and while the full impact of this change is still largely unknown, it may contribute to an
increase in chronic use and cannabis-related harms (Hall and Lynskey, 2016). While the
public perception of cannabis is changing, the literature on the adverse health and societal
effects of cannabis is growing (Brady and Li, 2014; Compton et al., 2014; Hall, 2009; Hall
and Degenhardt, 2009; Lynskey and Hall, 2000; Meier et al., 2012; Volkow et al., 2016). The
development of cannabis use disorder (CUD) is a potential adverse effect that may occur
among chronic users. Data comparing rates of cannabis use and CUD prevalence from
2001–2002 to 2012–2013 showed a more than doubling of cannabis use rates and prevalence
of CUD among adults, with three out of 10 users developing a CUD (Hasin et al., 2015).
This study found that the risk of developing a CUD did not increase, but CUD rates
increased due to the increased prevalence of use in the US.

Author Manuscript

Given the apparent increased prevalence of cannabis use among adults, healthcare settings
and substance use disorder (SUD) treatment centers may encounter more adults seeking
treatment for CUD or obtaining court-mandated treatment. While research focused on the
treatment of CUD is needed, the generalizability of results from clinical trials does not
always translate well to real-world practice settings (Humphreys, 2016; Rothwell, 2005).
Clinical trials often employ stringent exclusion criteria and tend to recruit small and
unrepresentative sub-samples of the target population. A recent analysis explored the
representativeness of study samples within the National Drug Abuse Treatment Clinical
Trials Network (CTN) compared to national US datasets (Susukida et al., 2016). The 10
CTN studies used in this analysis varied with respect to the intervention being tested and
particular substance of abuse being targeted by the intervention, though none were focused
specifically on cannabis use. This study found notable differences in the demographics of
those participating in research studies versus those entering SUD treatment, specifically in
the areas of education and employment. It is unknown, however, if similar differences exist
among those with CUD when compared to nationally representative samples. One study
found that the majority of adults meeting criteria for cannabis dependence through a
household survey would have been excluded from a clinical trial using common exclusion
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criteria (Okuda et al., 2010). Therefore, the representativeness of CUD clinical trial samples
is a timely issue given that novel therapeutics and treatment strategies are needed for CUD
and more treatment trials are likely in the near future. It is important to identify differences,
should they exist, among those who volunteer for randomized clinical trials compared to
other cannabis users in order to improve sample representativeness and the generalizability
of promising clinical trial results.

Author Manuscript

In order to address the question of sample representativeness in CUD clinical trials, this
study aimed to compare the demographics and cannabis use characteristics of adult
participants with CUD enrolled in a multi-site treatment trial for cannabis cessation with a
comparable population from national datasets. This clinical trial was conducted within the
CTN and recruited a geographically diverse sample through six study sites in the US. The
study sample was compared with two unique national samples of adults; 1) meeting criteria
for CUD (or cannabis dependence) through household surveys, and 2) entering publically
funded SUD treatment programs for CUD.

2. Methods
2.1. Participants and Study Procedures

Author Manuscript

This multi-site clinical trial evaluated a pharmacotherapy added to a behavioral intervention
for cannabis cessation among US adults (Achieving Cannabis Cessation: Evaluating NAcetylcysteine Treatment [ACCENT]). Methodological details for this study can be found
elsewhere (McClure et al., 2014). Briefly, participants were adult men and women (N=302)
between the ages of 18–50 years who met criteria for cannabis dependence (based on
Diagnostic and Statistical Manual of Mental Disorders (DSM IV (First, 1994)), were
interested in quitting, and had a positive urine cannabinoid test during the screening
assessment. Exclusion criteria were focused on safety concerns and aimed to appropriately
characterize the sample. The following exclusion criteria were employed: known allergy to
N-Acetylcysteine (NAC), pregnant or lactating, use of NAC-containing supplements or
hazardous concurrent medications, current enrollment in treatment for cannabis dependence,
use of synthetic cannabinoids, current substance dependence other than nicotine or caffeine
and/or positive urine drug screen (other than cannabis), on opioid-replacement therapy,
recent history of asthma, uncontrolled medical or psychiatric illness that could put the
participant at risk, and risk of homicide or suicide.

Author Manuscript

Eligible participants were randomized to receive NAC or matched placebo for 12 weeks.
Contingency management procedures were used for both experimental groups to reinforce
abstinence from cannabis during twice weekly study visits, in addition to a separate
compensation schedule targeting attendance at study visits. Six study sites across the US
participated in the ACCENT trial (Behavioral Health Services of Pickens County [Pickens,
SC], The APT Foundation [New Haven, CT], University of Kentucky Medical Center
[Lexington, KY], University of California, Los Angeles Integrated Substance Abuse
Programs [Los Angeles, CA], The University of Texas Health Science Center at San
Antonio [San Antonio, TX], and CODA, Inc. [Portland, OR]). This trial was registered with
Clinicaltrials.gov (NCT01675661), and completed study procedures in August 2015. The
institutional review boards at participating centers approved the study protocol, which was
Drug Alcohol Depend. Author manuscript; available in PMC 2017 September 06.

McClure et al.

Page 4

Author Manuscript

overseen by an independent National Institute on Drug Abuse-appointed Data and Safety
Monitoring Board. Cannabis abstinence outcomes from this trial are described elsewhere
(Gray et al., Under Review).
2.2 Measures
Sources of Data—Data from the ACCENT study were compared to three nationally
representative datasets. Due to some constraints introduced by the national datasets, six
ACCENT participants were excluded from this analysis. Four participants were 50 years of
age (national datasets include 50 as the lower limit of a larger range). Two participants had
less than an eighth grade education, leading to an insufficient comparator group. This
resulted in a final sample of 296 participants being included from the ACCENT study in the
current analysis.

Author Manuscript
Author Manuscript
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Three national datasets were compared with the ACCENT study sample: the National
Survey on Drug Use and Health (NSDUH), the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) 2012–2013 National Epidemiologic Survey on Alcohol and Related
Conditions-III (NESARC-III), and the Treatment Episodes Data Set – Admissions (TEDSA). The NSDUH is a publicly available dataset that measures the prevalence of drug use in
the US among a representative community dwelling population. NSDUH 2014 data were
used for this analysis (United States Department of Health and Human Services Substance
Abuse and Mental Health Services Administration, 2016). Weighting variables were used for
this dataset as recommended for the NSDUH. The NESARC-III includes data from noninstitutionalized, civilian adults (18 years or older) in the US. This survey employed
multistage probability sampling to choose respondents. A limited dataset from the
NESARC-III was used for the current analysis. Additional details regarding the NESARCIII are available elsewhere (Grant et al., 2014). Weighting variables were used for this
dataset. The TEDS-A includes data on treatment admissions (including court-mandated
admissions) to SUD programs that are publicly funded. We used the most recent TEDS-A
data available at the time, which was from 2013 (Substance Abuse and Mental Health
Services Administration; Center for Behavioral Health Statistics and Quality, 2015). Since
the ACCENT study only enrolled those who were cannabis dependent, had used cannabis in
the past 30 days, and were between the ages of 18–50; appropriate sub-samples were
selected from the national samples based on those variables (i.e., meeting criteria for
cannabis dependence or CUD [based on DSM-IV or DSM-5 criteria] of any severity level
and past 30 day use of cannabis [estimated based on past year use for the NESARC-III
dataset] and within the age of inclusion). The sample sizes from each data source are shown
in Table 1 for weighted and unweighted samples of the total records available and the
cannabis use sub-samples.
Demographics—Basic demographic information was obtained for all datasets. Response
options were collapsed for consistency across datasets, mostly for the ACCENT study
sample. The following demographic variables were used in the current analysis with the
following response categories: age (NSDUH: 18–20, 21–23, 24–29, 30–34, 35–49;
NESARC-III and TEDS-A: 18–20, 21–24, 25–29, 30–34, 35–39, 40–44, 45–49), sex (male,
female), race (Caucasian, African American, Other), ethnicity (Hispanic or Latino, non-
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Hispanic or Latino), education (9–11 years, 12 years or equivalent [no diploma, high school
graduate, GED or equivalent], >12 years), employment (working now, unemployed, or other
[not in the labor force, disability]), and marital status (never married, married/domestic
partnership, separated/divorced/widowed).
Cannabis and Tobacco Use—Measures of cannabis use and history included: age of
first use (11 and under, 12–14, 15–17, 18–20, 21 and over) and days of use in the past month
(NSDUH: continuous; NESARC-III and TEDS-A: 1–3 times in the past month, 1–2 times in
the past week, 3–6 times in the past week, or daily use). Tobacco use was also compared.
Tobacco use data was not available for the TEDS-A dataset. Tobacco use was categorized
based on use in the past month (daily tobacco user, non-daily tobacco user, no use in the past
month).

Author Manuscript

2.3. Statistical Analyses
Categorical variables from the national samples were compared to ACCENT variables using
a Pearson chi-squared test, accounting for the sample weight for comparisons of ACCENT
to NSDUH and NESARC-III. Frequencies were calculated using the sample weight for
NSDUH and NESARC-III. A Wilcoxon rank sum test was conducted to compare the
continuous variable, number of days of cannabis use in the prior 30 days, for ACCENT and
NSDUH, adjusting for sample weight.

Author Manuscript

Among the four datasets, there was minimal missing data (see Table 2 for rates of missing or
unknown data for each variable) and thus individuals with missing data were excluded from
the propensity score analyses. All available data was utilized for the chi-squared tests
reported in Table 2. The ACCENT study had three participants with missing data for race
(1%). The NSDUH and NESARC-III national datasets had missing data imputed and
information was obtained from the respective codebooks for each survey (Grant et al., 2014;
United States Department of Health and Human Services Substance Abuse and Mental
Health Services Administration, 2016). The NESARC-III dataset only have missing values
for the derived variables of past month cannabis use (0.8%) and current tobacco use (6.2%).
Missing values were not imputed in the TEDS-A dataset, and therefore had the most missing
data ranging from 0.4% for age of first THC use to 7% for marital status.

Author Manuscript

Propensity scores were calculated by modeling the probability of a participant being
enrolled in ACCENT, based upon characteristics collected at baseline of ACCENT and the
national sample. These characteristics included age, gender, race, ethnicity, education,
employment, marital status, and age at first cannabis use. Propensity scores were calculated
individually for each national dataset compared to ACCENT. For NSDUH, propensity
scores were also computed based on number of days of cannabis use in the past month and
cigarette smoking status. The baseline characteristics considered for NESARC-III also
included cannabis use in the past month and cigarette smoking status. Propensity scores for
TEDS-A were additionally based upon cannabis use in the past month. Logistic regression
was used to calculate the propensity scores for TEDS-A, and logistic regression adjusted for
the sample weight for NSDUH and NESARC-III.
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Introduced by Stuart and colleagues (Stuart et al., 2001), the propensity score-based index,
denoted Δp, assesses the similarity of clinical trial samples compared to target populations.
This propensity score-based index Δp was computed as the difference between the average
propensity scores of ACCENT and the national sample. Δp was standardized by dividing by
the pooled standard deviation of the propensity scores and can be used as an index of
similarity between samples with regards to all baseline characteristics used to compute the
propensity score. A difference of more than 0.25 standard deviations (standardized Δp) in
propensity score mean values indicates significant differences between the clinical trial and
the target population (Cochran and Rubin, 1973; Rosenbaum and Rubin, 1985; Stuart,
2010).

Author Manuscript

Two-sample t-tests were also conducted for comparison of the propensity scores between
ACCENT and the national sample, adjusted by sample weight for NSDUH and NESARCIII, and unadjusted for TEDS-A. All analyses were performed with SAS software, Version
9.4 of the SAS System for Windows (SAS Institute Inc., Cary, NC, USA), using the FREQ
procedure to calculate the chi-squared test and Wilcoxon rank sum test, and the LOGISTIC
procedure for logistic regression. The TTEST procedure was used for the t-test for the
comparison of ACCENT and TEDS-A, and the PROBT function was used to calculate the pvalue for the weighted comparisons of ACCENT to NSDUH and NESARC-III.

3. Results
3.1. Sample Comparisons

Author Manuscript
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Demographics—All comparisons to the ACCENT study sample are shown in Table 2.
Generally, the participants in the ACCENT trial were older, with less representation among
younger users (ages 18–20) and more representation among the older age group (45–49 for
NESARC-III and TEDS-A; 35–49 for NSDUH). All datasets showed greater numbers of
men being represented compared to women (nearly two-thirds were men), with differences
in gender distribution between ACCENT and NESARC-III data (fewer men and more
women in NESARC-III). Racial comparisons showed that among the household surveys
(NSDUH and NESARC-III), ACCENT had more representation of African Americans, but
lower proportions of other racial categories. TEDS-A data appeared to be more evenly
mixed among Caucasian and African Americans, but less representative of other races and
differed from ACCENT for all racial comparisons. ACCENT had a greater proportion of
Hispanic and Latino participants compared to all national samples, and participants in
ACCENT were also significantly more likely to have >12 years of education than the three
national datasets. Compared to household survey data, ACCENT participants had lower
rates of employment; though employment rates were higher for ACCENT when compared to
the TEDS-A data. Finally, the ACCENT sample had higher rates of married participants (or
domestic partnership) and lower rates of never married participants compared to NSDUH
and TEDS-A (but not NESARC-III).
Cannabis and tobacco use—Age of first cannabis use was generally comparable across
samples, with the exception of ACCENT having slightly higher rates of first use beyond the
age of 21 compared to the NSDUH dataset. Participants in the ACCENT sample had a
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significantly higher mean number of days of cannabis use in the 30 days prior compared to
NSDUH data (26.0 days versus 20.9 days). They were also significantly less likely to have
used cannabis 1 to 3 times in the past month and 1 to 2 times per week in the last month than
those in NESARC-III and TEDS-A. The ACCENT sample had higher rates of daily or
almost daily cannabis use. Finally, lower rates of daily tobacco use were found in ACCENT
compared to national samples (NSDUH and NESARC-III), as well as lower rates of nondaily smokers (NSDUH).
3.2. Propensity Scores

Author Manuscript

Propensity scores modeling the probability of being in ACCENT, based upon the baseline
characteristics, are shown in Table 3. The propensity scores are used to measure the
differences between the baseline characteristics of the ACCENT sample and the national
sample. Δp ranged from 0.0007 for NESARC-III to 0.0343 for TEDS-A, and standardized
Δp was 1.72 standard deviations for TEDS-A, 3.65 standard deviations for NSDUH, and
6.67 standard deviations for NESARC-III. These values exceed the 0.25 standardized Δp
cut-off, which indicates significant differences between ACCENT and the national samples
with respect to the demographics and cannabis use characteristics considered.

4. Discussion

Author Manuscript

Demographic, cannabis, and tobacco use characteristics were found to be different among a
cannabis cessation pharmacotherapy clinical trial sample conducted in the US compared to
national datasets of current adult cannabis users with CUD. The clinical trial sample from
ACCENT tended to be older; had more representation of African American and Hispanic/
Latino ethnicities; was more educated; and was more likely to be married (or in a domestic
partnership). The ACCENT sample had a greater representation of daily or almost daily
cannabis use, and a lower proportion of tobacco use.
Propensity score calculations showed that standardized Δp values were far beyond the
proposed cut-off for sample similarity (0.25) (Cochran and Rubin, 1973; Rosenbaum and
Rubin, 1985) , demonstrating that the ACCENT sample was significantly different from
national datasets. The TEDS-A dataset yielded the lowest standardized Δp, indicating this
population was the most similar to the ACCENT sample compared to the household surveys,
but still well beyond the cut-off. Differences may be expected between the TEDS-A and the
NSDUH/NESARC-III, given that the latter are household surveys and most cannabis users
interviewed for those surveys were not necessarily seeking treatment for their drug use. As
such, these national datasets represent unique populations of cannabis users, but none
demonstrated similarity to the ACCENT study sample.

Author Manuscript

These results are consistent with the Susukida and colleagues paper (2016), which found
differences within diverse CTN study samples and nationally representative samples,
specifically in the areas of education and employment. Similar to Susukida and colleagues
(2016), the current study found higher levels of education within the ACCENT sample
compared to national samples, though employment seemed to fall in between the TEDS-A
dataset (greater employment and less unemployment) and household surveys (less employed
and greater unemployment).
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An encouraging finding from this analysis was that the ACCENT study recruited a more
diverse racial and ethnic study sample. Racial and ethnic diversity of the sample was a study
priority; sites were selected and recruitment strategies were modified as needed throughout
enrollment in order to promote such diversity. Though males made up the majority of study
participants in ACCENT, this accurately reflects national estimates of cannabis users, with
nearly two-thirds of those with CUD or seeking treatment for cannabis use being male.
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The differences found from this analysis are not surprising given that sample
representativeness of clinical trials has been questioned (Humphreys, 2016; Rothwell, 2005),
but does illustrate the need to ensure representative samples for CUD clinical trials. There
are several potential avenues to improve sample representation. Alternative methods of
recruitment could be used to target populations that may not be as likely to engage in clinical
research, including those who are court-mandated to treatment for cannabis use as they
represent a substantial portion of those enrolled in treatment programs. Proactive methods of
recruitment could be used to contact a diverse population that might otherwise not contact
study teams through advertisements. For large clinical trials, multiple study sites are often
used and care should be taken in selecting these sites based on the patient/participant
population. The National Drug Abuse Treatment CTN is a network of affiliated research
centers, clinics, and collaborators, all with demographic data on the population of their
clinics or their previous recruitment performance. This is an advantage to conducting clinical
trials within the CTN platform, but all multi-site studies should strive for appropriate sites
and adequate diversity of the study sample. The cannabis using population and those
meeting for cannabis use disorder are a heterogeneous group and study samples should
adequately reflect that.
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Stringent inclusion/exclusion criteria continue to be a barrier to sample representativeness.
Exclusion criteria employed by most clinical trials impacts the generalizability and
representativeness of the sample, which has been demonstrated among those with cannabis
dependence in a community sample (Okuda et al., 2010), for other substances of abuse
(Blanco et al., 2008; Le Strat et al., 2011; Motschman et al., 2016), and among other medical
disorders (Humphreys et al., 2013). Studies should consider more inclusive criteria to
improve sample representativeness, when appropriate based on the phase of the study and
other potential factors (e.g., risks of study intervention). None of the proposed solutions to
improve sample representativeness are without challenges and inherent disadvantages, but
this should be an important consideration when designing CUD treatment trials moving
forward.
4.1. Limitations

Author Manuscript

This study has several limitations. First, the timeframe of data collection for the ACCENT
study and for all national datasets does not perfectly align to capture the same months or
years. However, all data used for comparisons were the most recent available datasets at the
time of this analysis. Second, the TEDS-A data only captures admissions to SUD treatment
clinics that received federal funds, thus excluding data from private facilities and a
potentially important group of cannabis users. Additionally, TEDS-A data includes both
those who were court-mandated to treatment compared to entering treatment on a more
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voluntary basis. Third, comparisons were made between national datasets and the ACCENT
study sample on demographic and clinical characteristics that were captured in a uniform
manner across surveys and could be categorized to be comparable. As such, a limited
number of characteristics were compared in this analysis and used in determining propensity
scores. Only observed characteristics can be accounted for using this statistical method.
4.2. Conclusions

Author Manuscript

The results from this analysis contribute to the body of literature suggesting that those who
participate in research and specifically randomized clinical trials may be different, in terms
of demographics and clinical characteristics, compared to national samples of the target
population. The sample from the ACCENT trial appear to be unique from both SUD
treatment admission data and household surveys, the latter of which may be more likely to
capture users of lower severity, higher functioning, and non-treatment seeking/accepting.
This may explain why the TEDS-A dataset and the ACCENT sample were closer in
propensity scores than the two community samples. Notably, this study was specific to
heavy cannabis users interested in quitting, which may be a population that will increase
over the next few years given changes in public perception and the regulatory status of
cannabis. Considering sample representativeness must be a key element through protocol
development, choice of exclusion criteria, and throughout trial enrollment in order to best
represent the clinical population in treatment studies and improve the generalizability of
promising treatment strategies.
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Author Manuscript

Weighted and unweighted sample sizes for CTN-0053 (ACCENT), NSDUH, NESARC-III, and TEDS-A.
ACCENT
Raw N
Raw N (unweighted)

302

Sample Subset N
Sample Subset N (unweighted)

296

NSDUH

NESARC-III

265,122,864

235,411,957

55,271

36,309

1,832,081

4,765,117

524

766

TEDS-A

1,683,451

28,955

Author Manuscript
Author Manuscript
Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript
70 (23.6%)
56 (18.9%)
45 (15.2%)
35 (11.8%)
24 (8.1%)
28 (9.5%)

21–24

25–29

30–34

35–39

40–44

45–49

0.343

Drug Alcohol Depend. Author manuscript; available in PMC 2017 September 06.
38 (12.8%)
3 (1.0%)

Other

Missing/Unknown/Refused

Not Hispanic or Latino

231 (78.0%)

82 (27.7%)

African American

Ethnicity

173 (58.4%)

0 (0%)

Caucasian

Race

Missing/Unknown/Refused

1,517,396 (82.8%)

0 (0%)

434,091 (23.7%)

408,037 (22.3%)

989,954 (54.0%)

0 (0%)

555,289 (30.3%)

0.029

0.029

<.001

0.025

0.128

<.001

0.396

83 (28.0%)

<.001

Female

1,276,793 (69.7%)

335,267 (18.3%)

244,206 (13.3%)

0.396

87 (29.4%)

35–49

0.544

213 (72.0%)

45 (15.2%)

30–34

505,438 (27.6%)

0.044

Male

77 (26.0%)

24–29

391,057 (21.3%)

0.004

<.001

0.396

49 (16.6%)

21–23

356,114 (19.4%)

P-value1

Gender

38 (12.8%)

18–20

Age (NSDUH)

38 (12.8%)

18–20

Age (NESARC-III and TEDS-A)

NSDUH
N (%)

Demographics

ACCENT
N (%)

3,991,554 (83.8%)

0 (0%)

1,074,555 (22.6%)

982,732 (20.6%)

2,707,830 (56.8%)

0 (0%)

1,644,364 (34.5%)

3,120,753 (65.5%)

235,906 (5.0%)

359,299 (7.5%)

325,796 (6.8%)

676,551 (14.2%)

753,567 (15.8%)

1,347,026 (28.3%)

1,066,972 (22.4%)

NESARC-III
N (%)

0.008

0.008

<.001

0.003

0.574

<.001

0.019

0.019

0.019

<.001

0.711

<.001

0.620

0.143

0.078

<.001

<.001

P-value1

26,248 (90.7%)

444 (1.5%)

2,350 (8.1%)

12,072 (41.7%)

14,089 (48.7%)

7 (0.0%)

8,362 (28.9%)

20,586 (71.1%)

1,072 (3.7%)

1,675 (5.8%)

2,648 (9.1%)

4,571 (15.8%)

6,599 (22.8%)

7,212 (24.9%)

5,178 (17.9%)

TEDS-A
N (%)

Comparison of demographic, cannabis and tobacco use characteristics from CTN-0053 (ACCENT) to NSDUH, NESARC-III, TEDS-A.

Author Manuscript

Table 2

<.001

<.001

0.003

<.001

<.001

<.001

0.751

0.745

0.749

<.001

0.089

0.112

0.784

0.114

0.618

0.024

<.001

P-value1
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Missing/Unknown/Refused

29 (9.8%)

Widowed, Separated, or Divorced
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115 (38.9%)
34 (11.5%)
17 (5.7%)

15–17

18–20

21 and Over

Mean (SD)

N

Days of Cannabis Use in 30 Days Prior

26.0 (6.25)

296

0 (0%)

105 (35.5%)

12–14

Missing/Unknown/Refused

25 (8.4%)

20.9 (9.90)

1,832,081

0 (0%)

14,969 (0.8%)

279,010 (15.2%)

780,595 (42.6%)

626,703 (34.2%)

130,804 (7.1%)

0 (0%)

113,410 (6.2%)

278,791 (15.2%)

1,439,881 (78.6%)

0 (0%)

279,146 (15.2%)

Cannabis Use

11 and Under

Age of First THC Use

0 (0%)

77 (26.0%)

Missing/Unknown/Refused

190 (64.2%)

Married/Domestic Partnership

0 (0%)

Never Married

Marital Status

Missing/Unknown/Refused

56 (18.9%)

Other (including out of labor force)

<.001

<.001

0.073

0.191

0.646

0.383

<.001

0.010

<.001

<.001

<.001

0.078

<.001

90 (30.4%)

Unemployed

228,125 (12.5%)

<.001

1,324,811 (72.3%)

150 (50.7%)

Working Now

<.001

0.579

<.001

<.001

0.029

<.001

0 (0%)

933,872 (51.0%)

615,877 (33.6%)

282,333 (15.4%)

0 (0%)

314,686 (17.2%)

Employment Status

0 (0%)

182 (61.5%)

>12th Grade (some college, Associate's, Bachelor's, Master's, Professional
School, or Doctoral degree)

Missing/Unknown/Refused

95 (32.1%)

19 (6.4%)

0 (0%)

65 (22.0%)

12th Grade or Equivalent (no diploma, high school graduate, or GED or
equivalent)

9th to 11th Grade

Education

Author Manuscript

Hispanic or Latino

P-value1

Author Manuscript
NSDUH
N (%)

0 (0%)

177,602 (3.7%)

707,720 (14.9%)

1,960,077 (41.1%)

1,601,822 (33.6%)

317,897 (6.7%)

0 (0%)

452,630 (9.5%)

1,247,987 (26.2%)

3,064,500 (64.3%)

0 (0%)

943,601 (19.8%)

1,209,870 (25.4%)

2,611,646 (54.8%)

0 (0%)

2,630,464 (55.2%)

1,433,841 (30.1%)

700,812 (14.7%)

0 (0%)

773,563 (16.2%)

NESARC-III
N (%)

0.067

0.103

0.425

0.499

0.221

0.109

0.861

0.945

0.965

0.984

0.703

0.047

0.153

0.137

0.030

0.452

<.001

<.001

0.008

P-value1

128 (0.4%)

1,446 (5.0%)

3,348 (11.6%)

10,096 (34.9%)

10,616 (36.7%)

3,321 (11.5%)

2,039 (7.0%)

2,756 (9.5%)

2,721 (9.4%)

21,439 (74.0%)

212 (0.7%)

5,623 (19.4%)

14,938 (51.6%)

8,182 (28.3%)

278 (1.0%)

5,107 (17.6%)

13,382 (46.2%)

10,188 (35.2%)

318 (1.1%)

2,389 (8.3%)

TEDS-A
N (%)

Author Manuscript

ACCENT
N (%)

0.556

0.967

0.153

0.672

0.104

0.393

0.871

<.001

<.001

<.001

0.828

<.001

<.001

<.001

<.001

<.001

<.001

<.001

<.001

P-value1
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Min, Max

136 (45.9%)
157 (53.0%)

3–6 Times per Week

Daily in the Past Month

80 (27.0%)

Current Smoker - Daily
0 (0%)

52 (17.6%)

Current Smoker - Less than Daily

Missing/Unknown/Refused

164 (55.4%)

Non-smoker

Current Tobacco Use

0 (0%)

615,402 (33.6%)

665,401 (36.3%)

551,279 (30.1%)

Tobacco Use

0 (0.0%)

3 (1.0%)

1–2 Times per Week

Missing/Unknown/Refused

0 (0.0%)

1, 30

3, 30

1–3 Times in the Past Month

25 (12, 30)

30 (23, 30)

0.017

<.001

<.001

<.001

293,191 (6.2%)

2,511,717 (52.7%)

863,389 (18.1%)

1,096,821 (23.0%)

38,802 (0.8%)

1,668,024 (35.0%)

1,938,976 (40.7%)

495,604 (10.4%)

623,711 (13.1%)

NESARC-III
N (%)

<.001

0.805

<.001

<.001

<.001

0.066

<.001

<.001

<.001

P-value1

508 (1.8%)

13,900 (48.0%)

4,679 (16.2%)

4,142 (14.3%)

5,726 (19.8%)

TEDS-A
N (%)

0.085

<.001

<.001

<.001

<.001

P-value1

Pearson chi-squre test was conducted for all characteristics other than number of days of use in prior 30 days, where a Wilcoxon rank sum test was conducted. Numbers in bold indicate statistically
significant differences between ACCENT and survey samples at p<0.05.

1

Author Manuscript

Past Month Use

Author Manuscript

Median (25th, 75th)

P-value1

Author Manuscript
NSDUH
N (%)

Author Manuscript

ACCENT
N (%)
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Author Manuscript

Author Manuscript

Author Manuscript
0.0008
0.0452

NESARC-III2

TEDS-A3
0.0109

0.0001

0.0002

Survey

0.0343

0.0007

0.0008

Δp

0.0199

0.0001

0.0002

Pooled
standard
deviation

1.72

6.67

3.65

Standardized
Δp

29.35

114.13

62.40

t-test

<.001

<.001

<.001

p-value

Propensity score calculated based on age, gender, race, ethnicity, education, employment, marital status, age at first cannabis use, and cannabis use in the past month.

Propensity score calculated based on age, gender, race, ethnicity, education, employment, marital status, age at first cannabis use, cannabis use in the past month, and cigarette smoking status.

3

2

Propensity score calculated based on age, gender, race, ethnicity, education, employment, marital status, age at first cannabis use, number of days of cannabis use in the past month, and cigarette smoking
status.

1

0.0010

ACCENT

NSDUH1

Survey

Mean propensity
score

Comparison of propensity scores between CTN-0053 (ACCENT) and NSDUH, ACCENT and NESARC-III, and ACCENT and TEDS-A.
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